Position:
Professor
Section Head, Sepsis and Multiple Organ Failure, Faculty of Medicine
Division:
Critical Care Medicine
Research Interests:

The two major current themes of Dr. Russell’s research are 1) the genomics and pharmacogenomics of septic shock and 2) randomized controlled trials in patients with septic shock.

1)Genomics and Pharmacogenomics of Septic Shock

Dr. Russell has over 200 peer-review publications and continues an active research program investigating genomics of septic shock with discoveries genetic variants (single nucleotide polymorphisms (SNP)) of key coagulation, inflammatory and innate immunity genes. We do gene association studies in : septic shock and cardiovascular surgery patients. Dr. Russell collaborates closely with Drs. Keith Walley and John Boyd of SPH and HLI.

Dr. Russell has held grants for genomics from CIHR to study susceptibility genes as well as peer-review grants to fund studies of genotype in sepsis, post-cardiopulmonary bypass (CO-PI CIHR grant), ARDS (grants from BC Lung Association and Providence Health Care) and acute lung injury (NIH SCCOR/University of Washington).

We have found significant relationships of genetic markers (single nucleotide polymorphisms) of protein C, IL-6, IL-8, IL-10, VPS13D, TNFAIP2, SVEP1 and fibrinogen with increased risk of organ dysfunction and death in sepsis. In contrast, SNPs of innate immune genes CD14, MBL, TLR-2 and TLR-1 are associated with increased risk of severe infection (sepsis).

Dr. Russell also has an active research program in pharmacogenomics of septic shock. We have identified genotypes – predictive biomarkers – that alter predicted response to therapies vasopressin. We also identified the genetic mechanism of an important promotor SNP of protein C. We have also completed and are reporting the largest pharmacogenomics trial of any therapy in septic shock, a multicenter pharmacogenomics biomarker study in matched patients with severe sepsis treated with or without activated protein C.

2) Clinical Trials in Septic Shock

Dr. Russell has an active randomized controlled trials (RCTs) program in critical care (ARDS, ALI), asepsis and septic shock. We have led clinical trials of many promising drug candidates in sepsis including vasopressin in septic shock (CIHR funded), ibuprofen (NIH grant-funded), antioxidants, IL-1ra, anti-TNF, interleukin-10, tissue factor pathway inhibitor, and activated protein C.

Dr. Russell has a particular interest in vasopressin in septic shock. He was principal Investigator  of a CIHR-funded multicenter, randomized controlled trial of vasopressin vs. norepinephrine in septic shock (VASST) published in the New England Journal of Medicine (Russell JA, et al. Vasopressin vs. norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877-887). Low does vasopressin is comparable in efficacy and safety to norepinephrine and may be more effective than norepinephrine in less severe septic shock. The VASST study is cited in the 2008 and 2013 international sepsis treatment guidelines. To date Dr. Russell has 40 peer-reviewed publications related to vasopressin and arising from VASST as well as 12 chapters and reviews.

The activity of vasopressin can be improved by using a selective V1a agonist, selepressin. Dr. Russell was PI of a Phase 2A proof-of-principle RCT of selepressin in septic shock (Sponsor Feriring). Selepressin decreased fluid overload and need for vasopressors and ventilation.

Dr. Russell’s research success in sepsis was recognized by a prestigious invited review in the New England Journal of Medicine (Russell JA. Management of sepsis. N Engl J Med 2006; 355(16): 699-713.

Education:
Princeton University, A.B. Biology (Cum Laude)
University of Toronto, MD
University of Toronto, Internal Medicine Residency
University of California, San Francisco, Critical Care Medicine and Research Fellowship
Affiliations
Member, Editorial Board, Journal of Innate Immunity, 2008 – present
Member, Editorial Board, American Journal of Respiratory and Critical Care Medicine, 2012 – present
Member, Editorial Board, Annals of Intensive Care, 2012 – present
Member, Editorial Board, Intensive Care Medicine, 2015 – present
Recent Publications:
  • Sutherland AM, Sham AHP, Wurfel MM, Walley KR, Russell JA. A Non-synonymous polymorphism of IRAK4 associated with increased prevalence of Gram-positive infection and decreased response to Toll-like receptor ligands. J Innate Immune (In press, 2011).
  • Boyd JH, Forbes J, Nakada T, Walley KR, Russell JA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med October 21, 2010 [Epub ahead of print].
  • Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Stors MM, Holmes CL Hebert JC, Cooper DJ, Mehta S, Granton JT, Cook DJ, Presneill JJ for the Vasopressin and Septic Shock Trail (VASST) Investigators.  The effects of vasopressin on acute kidney injury in septic shock.  Intensive Care Med 36(1): 83. 2010.
  • Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Stors MM, Holmes CL Hebert JC, Cooper DJ, Mehta S, Granton JT, Cook DJ, Presneill JJ for the Vasopressin and Septic Shock Trail (VASST) Investigators. The effects of vasopressin on acute kidney injury in septic shock.  Intensive Care Med 36(1):83, 2010.
  • Nakada T, Boyd JH,Aguirre-Hernandez R, Thain K, Thair S, Nakada E, McConechy M, Russell JA, Walley KR. Beta2-receptor gene polymorphism is associated with mortality in septic shock. Am J Resp Crit Care Med 181: 143-149, 2010.
  • Nakada T, Boyd JH,Aguirre-Hernandez R, Thain K, Thair S, Nakada E, McConechy M, Russell JA, WalleyKR. Beta2-receptor gene polymorphism is associated with mortality in septicshock. Am J Resp Crit Care Med 181:143-149, 2010.
  • Russell JA, Boyd JH, Nakada T, Thair SA, Walley KR. Molecular mechanisms of sepsis. Contrib Microbiol (In press, 2010).
  • Russell JA, Gordon AC, Walley KR. Interaction of vasopressin infusion, corticosteroid treatment and mortality of septic shock. Corticostoids and the original vasopressin and septic shock trial subgroups. Crit Care Med 38(1) 338-339, 2010.
  • Russell JA, Wally KR.  Vasopressin and its immune effects in septic shock. J Innate Immun 2:446-360, 2010.
  • Russell JA.  Are copy number variants of defensins a key source of variation in the orchestrated response to infection? Anesthesiol 112(6):1307-1308, 2010.
  • Russell JA.  Vasopressin in septic shock. Minerva Anestesiol (In press, 2010).
  • Russell JA. Gene expression in human sepsis. What have we learned? Crit Care 15:121, 2010.
  • Russell JA. Prone positioning in patients with acute respiratory distress syndrome. JAMA. 303(9):832, 2010 (Letter).
  • Russell JA. Vasopressin in the management of septic shock. Crit Care (In press, 2010).
  • Russell JA. Vasopressin, levosimendan and cardiovascular function in septic shock. Crit Care Med 38(10): 2071-2073, 2010.
  • Thair SA, Walley KR, Nakada T, McConechy MK, Boyd JH, Russell JA. A single nucleotide polymorphism in NF-B inducing kinase is associated with mortality in septic shock. J Immunol  (In press, 2011).
  • von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton-Pipkin F, Cote AM, Douglas JM, Gruslin A, Hutcheon JA, Joseph KS, Kyle PM, Lee T, Loughna P, Menzies JM, Merialdi M, Millman AL, Moore MP, Moutquin JM, Ouellet AB, Smith GN, Walker JJ, Walley KR, Walters BN, Widmer M, Lee SK, Russell JA, Magee LA for the PIERS Study Group. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation fo the fullPIERS model. Lancet December 23, 2010 [Epub ahead of print].
  • Hodder RV, Hall R, Russell JA, Fisher HN, Lee B.  Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.  Crit Care. 13(3):R78, 2009.
  • Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D for the VASST investigators. Interaction of vasopressin infusion, corticosteroid treatment and mortality of septic shock. Crit Care Med 37(3):811-818, 2009.
  • Russell JA. Vasopressin and its copilot copeptin in sepsis and septic shock. Crit Care Med 37(2): 749 – 750, 2009.
  • Shaw DM, Sutherland AM, Russell JA, Lichtenstein SV, Walley KR.  Novel polymorphism of interleukin-18 associated with greater inflammation after cardiac surgery.  Crit Care 29;13(1):R9, 2009.
  • Meade MO, Cook DJ, Guyatt, GH, Slutsky AS, Arabi YM, Cooper DJ, Davies AR, Hand LE, Zhou Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell J, Skrobnik Y, Ronco JJ, Stewart TE, and LOVS investigators.  Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 299(6): 637 – 645, 2008.
  • Morris P, Vincent JL, Russell JA, Wheeler A, Bernard GR. A double-blind placebo-controlled study to evaluate the safety and efficacy of procysteine in the treatment of patients with acutr respiratory distress syndrome. Crit Care Med 36 (3): 782 – 788, 2008.
  • Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D for the VASST investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358: 877 – 887, 2008.
  • Russell JA, Walley KR.Vasopressin in septic shock. N Engl J Med 358: 2736 -2738, 2008.
  • Russell JA, Wellman H, Walley KR. Protein C rs2069912 C allele is associated with increased mortality from severe sepsis in North Americans of East Asian ancestry. Hum Genet 123: 661 – 663, 2008.
  • Russell JA. The current management of septic shock. Minerva Medica 99(5): 431 – 458, 2008.
  • Wurfel MM, Gordon AC, Holden TD, Radella F, Strout J, Kalikawa O, Ruzinski JT, Rona G, Black RA, Stratton S, Jarvik GP, Hajjar AM, Nickerson DA, Rieder M, Sevransky J, Maloney JP, Moss M, Martin G, Shanholz C, Garcia J, Gao L, Brower R, Barnes KC, Walley KR, Russell JA, Marin TR. TLR-1 polymorphisms confer higher innate immune responses and susceptibility to death in sepsis. Am J Resp Crit Care Med 178: 710 – 720, 2008.
  • Manocha S, Russell JA, Sutherland AM, Wattanathum A, Walley KR. Fibrinogen-beta gene haplotype clade is associated with mortality in sepsis. J Infection  54:572-7 2007  (doi:10.1016/j.inf.2006.10.001).
  • Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J, Douglas MJ, Gruslin A, Kyle P, Lee SK, Moore MP, Moutquin JM, Smith GN, Walker JJ, Walley KR, Russell JA, von Dadelszen P. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy.  26:447-62. 2007.
  • Russell JA. Management of sepsis. N Engl J Med 2007; 356: 1178-82 (letter reply).
  • Russell JA. Vasopressin in septic shock.  Crit Care Med. 35:S609-15. 2007.
  • Russell JA. Vasopressin in vasodilatory and septic shock. Curr Opin Crit Care. 13:383-91. 2007.
  • Tokunaga, C, Russell JA, Walley KR. Albumin resuscitation improves ventricular contractility and myocardial tissue oxygenation in rat endotoxemia.  Crit Care Med. 35:1341-7. 2007.
  • Walley KR, Russell JA. Protein C -1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit Care Medicine 2007; 35(1): 12-17.
  • Bernard GR, Dhainaut JF, PhD, Russell JA, Shorr A, Macias WL, Nelson  DR, Sundin DP. Protein C Concentrations in Severe Sepsis: Early Directional Change in Plasma Levels Predict Outcome. Crit Care 2006; ccforum.com/content/10/3/R92  (open access).
  • Fink M, et al. The future of our specialty: critical care medicine a decade from now. Crit Care Med (In press 2006).
  • Gordon A, Rusell JA. Goal-directed therapy: how long can we wait? Crit Care 2006; 9(6): 647-8.
  • Gordon A, Russell JA. Goal-directed therapy: how long can we wait? Crit Care 2006; 9(6): 647 -8.
  • Manocha S, Gordon A, Ebrahim S, Groshaus H, Walley KR, Russell JA. Inhaled beta-2 agonist salbumtamol in acute lung injury: an association with improvement in acute lung injury. Crit Care 2006; 10: R12-R18.
  • Manocha S, Gordon A, Ebrahim S, Groshuas H, Walley KR, Russell JA. Inhaled beta-2 agonist salbumtamol in acute lung injury: an association with improvement in acute lung injury. Crit Care 2006; 10: R12 -R18.
  • Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, Edens, TR, Bernard GR. Safety and efficacy of affinity purified, anti-tumor necrosis factor-alpha, ovine Fab for injection (CytoFAb™) in severe sepsis. Crit Care Medicine 2006; 34 (9): 2271 -2281.
  • Russell JA. Management of sepsis. N Engl J Med 2006; 355 (16): 699-713.
  • Sutherland A, Gordon A, Russell JA. Are vasopressin levels increased or decreased in septic shock? Crit Care Medicine 2006; 34 (2): 542 -543.
  • Sutherland A, Gordon A, Russell JA. Are vasopressin levels increased or decreased in septic shock? Crit Care Medicine 2006; 34 (2): 542-543.
  • Wheeler AP, Bernard GR, Thompson BT, et al of NHLBI ARDSnet. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354 (21): 2213 -2211. (J. Russell was Site PI of UBC site of ARDSnet).
  • Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, de Boisblanc B and NHLBI ARDSnet. Comparison of two fluid management strategies in acute lung injury. N Engl J Med 2006; 354 (24): 2564 -2575. (J. Russell was Site PI of UBC site of ARDSnet).
  • Linder A, Russell JA.Long-term (10 year) mortality of younger previously healthy severe sepsis patients is worse than nonseptic patients and general population. Crit Care Med43(2):e57-e58, 2015.
  • Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, Chiche JD, Parks T, Chapman SJ, Davenport EE, Elliott KS, Bion J, Lichtner P, Meitinger T, Wienker TF, Caulfield MJ, Mein C, Bloos F, Bobek I, Cotogni P, Sramek V, Sarapuu S, Kobilay M, Ranieri M, Rello J, Sirgo G, Weiss YG, Russwurm S, Schneider M, Reinhart K, Holloway PAH, Knight J, Garrard CS, Russell JA, Walley KR, Stüber F, Hill AVS, Hinds CJ, for the ESICM/ECCRN GenOSept Investigators. Genome-wide association study of survival from sepsis due to pneumonia. Lancet Resp Med3(1):53 – 60, 2014.
  • Wong H, Walley K, Pettila V, Meyer N, Russell J, Karlsson S, Shashaty M, Lindsell C. Comparing the prognostic performance of ASSIST tointerleukin-6 and procalcitonin in patients with severesepsis or septic shock.Biomarkers12:1-4, 2015.
  • Nakada T, Russell JA, Wilkinson M, Aguirre R, McConechy M, Fjell C, Nakada E, Boyd JH,Thair SA, Walley KR. Identification of a non-synonymous polymorphism in the SVEP1 gene associated with altered clinical outcomes in septic shock.Crit Care Med 43(1):101- 108, 2015. doi: 10.1097/CCM.0000000000000604.
  • Nakada T, Thair S, Russell JA, Boyd JH, Walley KR. VPS13D gene variant is associated with altered IL-6 production and mortality in septic shock. J Inn Immmunity7:545-553, 2015.
    Bentzer P, Russell JA, Walley KR. Advances in sepsis research. Clin Chest Med36(3):521–530, 2015. doi: 10.1016/j.ccm.2015.05.009.
  • Russell JA, Møller MH, Annane D. Early goal-directed therapy: from discovery through enthusiasm to equipoise?Int Care Med41(9):1676- 1678, 2015.DOI 10.1007/s00134-015-3857-3.
  • Russell JA, Walley KR.Sepsis breakthroughs in 2014.F1000 Research4 (F1000 Faculty Rev):131, 2015 (doi: 10.12688/f1000research.6565.1).
  • LinderA, ArnoldR, BoydJH, ZindovicM, ZindovicI, Lange-JendebergA, PaulssonM, NybergP, RussellJA, PritchardD, ChristenssonB,ÅkessonP. Heparin-binding protein measurement improves the prediction of severe infection with organ dysfunction in the emergency department. Crit Care Med 43;2378 – 2386, 2015.
  • Russell JA. C-terminal portion of pro-arginine-vasopressin(CT-PRO-AVP) as a predictive biomarker in sepsis – Not there yet. Shock 44(4):381-2, 2015.
    Walley KR, Francis GA, Opal SM, Stein EA, Russell JA, Boyd JB.The central role of PCSK9 in pathogen lipid transport and clearance. Am J Resp Crit Care Med 192:1275 – 1286,2015.PMID:26252194.
  • ThairSA, TopchiyE, BoydJH, CirsteaM, WangC, NakadaT, FjellC, WurfelM, RussellJA, Walley KR.Tumor Necrosis Factor alpha induced protein 2 (TNFAIP2) inhibits early TNF [alpha] induced NF-[kappa]B signaling and decreases survival in septic shock patients. J Inn Immunity 8:57 – 66, 2016. (Sept 15, 2015 Epub.)
  • Douglas J, Russell JA. The role of genomics to identify biomarkersand signaling molecules during severe sepsis.Minerva Anestesiologica82 (3):343-58, 2016.
  • Harhay MO, Russell JA. Designing better, not just bigger, multicenter critical care trials.Crit Care Med 44(1):e48 – e49, 2016.
  • Wang F,Meyer N, Walley KR, Russell JA, Feng R. Causal genetic inference using haplotypes as instrumental variables. Genetic Epidemiology 40(1):35 – 44, 2016.
  • Asfar P, Russell JA, Tuckermann J, Radermacher P. Selepressin in septic shock –a step towards “decatecholaminization”? Crit Care Med 44(1):234 – 236, 2016.
  • Boyd JH, Fjell C, Russell JA, Sirounis D, Cirstae M, Walley KR. Increased PCSK9 levels during the development of cardiovascular and respiratory failure. J Innate Imm8:211 – 220, 2016. DOI:10.1159/000442976.
  • Gelinas J, Russell JA. Vasopressors during sepsis: selection and targets. Clinics in Chest Medicine37(2):251 – 262, 2016.
  • Genga K, Russell J. Early liberal fluids in sepsis patients are harmful.Crit Care Med 44(12):2258 – 2262, 2016. (epub May 13, 2016 -doi: 10.1097/CCM.0000000000001829).
  • Russell JA, Williams M. Trials in critical care that show increased mortality of the new intervention – inevitable or preventable mishaps? Ann Int Care 6:17, 2016.
  • Fisher J, Douglas JJ, Boyd JH, Walley KR. Russell JA. Elevated plasma angiopoietin-2 levels are associated with fluid overload, organ dysfunction and mortality in human septic shock.Crit Care Med 44(11): 2018 – 2027, 2016.doi: 10.1097/CCM.0000000000001853.
  • Linder A, Fisher J, Boyd J, Walley KR, Russell JA. Short-term organ dysfunction is associated with long-term (10 year) mortality of septic shock. Crit Care Med 44(8):e728-36, 2016. doi: 10.1097/CCM.0000000000001843.
  • Pisitsak C, Lee JGH, Boyd J, Coxon H, Russell JA, Walley KR. Increased ratio of visceral to subcutaneous adipose tissue in septic patients is associated with adverse outcome. Crit Care Med 44(11):1966 – 1973, 2016.doi: 10.1097/CCM.0000000000001870.
  • MebazaaA, Laterre PF, Russell JA, Bergmann A, Angus D, Gattinoni L, Gayat E, Harhay M, Hartmann O, Hein F, Kjolbye AL, Legrand M, Lewis RJ, Marshall J, Marx G, Radermacher P, Schroedter M, Scigalla P, Struck J, Van Den Berghe G, Yilmaz MB. Considerations for clinical endpoint selection in sepsis Phase 3 trials. J Int Care4:24,2016.DOI: 10.1186/s40560-016-0151-6.
  • Bentzer P, Fjell CD, Walley KR, Boyd J, Walley KR, Russell JA. Plasma cytokine levels predict response to corticosteroids in septic shock. Int Care Med Exp 42(12):1970 – 1979, 2016.
  • Topchiy E, Cirstea M, Kong HJJ, Boyd JH, Wang Y, Russell JA, Walley KR. Lipopolysaccharideiscleared from the circulation by hepatocytes via the Low Density Lipoprotein Receptor. PlosOne2016 May 12. http://dx.doi.org/10.1371/journal.pone.0155030.
  • Russell JA. Genomics and pharmacogenomics of sepsis – so close and yet so far. Crit Care 20:185, 2016.DOI 10.1186/s13054-016-1374-6.
  • Reuter DA, Russell JA, Mekonto Dessap A.Beta-blockers in septic shock to optimize hemodynamics-pro.Int Care Med 42(10): 1607 – 1609, 2016.(Online first September 2016).
    Russell JA. Physician culture and vasopressin use in septic shock. Ann ATS13(10):1677 – 1679, 2016.
  • Suetrong B, Pisitsaka C, Boyd JB, Russell JA, Walley KR. Hyperchloremia and moderate increase in serum chloride are associated with acute kidney injury in severe sepsis and septic shock patients. Critical Care20:315, 2016. DOI:10.1186/s13054-016-1499-7
  • Bentzer P, Fisher J, Kong J, Morgelin M, Boyd JH, Walley KR, Russell JA, Linder A. Heparin-binding protein is important for vascular leak in sepsis. Int Care Med Exp 4:33, 2016.
  • Perner A, Gordon A, de backer D, Dimopoulos G, Lipman J, Jensen JU, Russell JA, Myburgh J, Singer M, Bellomo R, Walsh T. Sepsis – Frontiers in diagnosis, resuscitation and antibiotic therapy. Int Care Med 42(12):1958 – 1969, 2016.
  • Russell JA. Vasopressin, norepinephrine, and vasodilatory shock after cardiac surgery – another “VASST difference?Anesthesiology 126:9 – 11, 2016
  • Dunser M, Russell JA. Getting down to the real question: effects of transfusion triggers on long-term survival and quality of life following septic shock. Int Care Med42(11):1766 – 1769, 2016.
  • Cirstea M, Walley KR, Russell JA, Boyd JH. Low plasma HDL concentration is an early prognostic biomarker of poor outcome in sepsis. J Crit Care38:289 – 294, 2017.
  • Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, Tidmarsh GF. Angiotensin II for the Treatment of High Output Shock 3 (ATHOS-3): a study protocol for a Phase 3 double-blinded randomized controlled trial. Crit Care Resuscitation19(1):43-49, 2017.
  • Russell JA, Lee T, Singer J, Boyd J, Walley KR. The new septic shock 3.0 definition and trials: a VASST experience. Crit Care Med 45(6):940 – 948, 2017. doi:10.1097/CCM.0000000000002323.
  • Genga K, Lo C, Cirstea M, Zhou G, Walley KR, Russell JA, Levin A, Boyd J. 2-year follow-up of septic patients presenting with low HDL: the effect upon acute kidney injury, death and eGFR. J Int Med2017, 281(5):518–529.
  • Rush B, McDermid RC, Celi LA, Walley KR, Russell JA, Boyd JH. Association between chronic exposure to air pollution and mortality in the acute respiratory distress syndrome. J Env Pollution 2017, 224:352-356. doi: 10.1016/j.envpol.2017.02.014.
    Fisher J, Boyd J, Walley KR, Russell JA, Linder A. Heparin-binding Protein (HBP): a prognostic and causative biomarker of Acute Kidney Injury and a potential target for heparin treatment in human septic shock. Shock 2017, 48(3):313-320. doi: 10.1097/SHK.0000000000000862.
  • Genga KR, Russell JA. How much excess fluid impairs outcome of sepsis? Int Care Med 43(5):680 – 682, 2017.
  • Rush B, Wiskar K, Celi L, Walley KR, Russell JA, McDermid R, Boyd JH. Association of household income level and in-hospital mortality in sepsis patients: a nationwide retrospective cohort analysis. J Intensive Care2017. an 1:885066617703338. doi: 10.1177/0885066617703338.
  • Perner A, Gordon AC, Angus DC, Lamontagne F, Machado F, Russell JA, Timsit JF, Myburgh J, Shankar-Hari M, Singer M. The intensive care medicine research agenda on septic shock. Int Car Med 2017, 43(9):1294-1305. doi: 10.1007/s00134-017-4821-1.
  • Genga KR, Russell JA. Update of sepsis in the ICU.J Inn Immunity 2017,9:441-455.
  • Russell JA, Vincent JL, Kjolbye AL, Olsson H, Blemings A, Spapen H, Carl P, Laterre PF, Grundemar L. Selepressin, a novel selective vasopressin V1aagonist, is an effective substitute for norepinephrine in a Phase IIA randomized placebo- controlled trial in septic shock patients. Crit Care 21:213, 2017.
  • Annane D, Pastores SM, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Meduri GU, Olsen KM, Rochwerg B, Rodgers, Russell JA, Van den Berghe G. Guidelines for the diagnosis and management of critical illness related corticosteroid insufficiency (CIRCI) in critically ill adult and pediatric patients (Part I. from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Int Care Medand Crit Care Med2017, 45(12):2078-2088.
  • Annane D, Pastores SM, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Meduri GU, Olsen KM, Rochwerg B, Rodgers, Russell JA, Van den Berghe G. Critical Illness-Related Corticosteroid Insufficiency (CIRCI): A Narrative Review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM).
    Int Care Medand Crit Care Med2017, 45(12):2089-2098.
  • Teboul JL, Duranteau J, Russell JA. Novel vasopressors for septic shock.Int Care Med. 2017 Aug 31. doi: 10.1007/s00134-017-4909-7.
  • Lewis R, Angus D, Laterre P, Kjolbye AL, Blemings A, Graves T, Russell J, Carlsen J, Jacoben K, Yealy D, Opal S, Windelov N, Francois B, Perner A, Pickkers P, Berry S. Rationale and design of an adaptive Phase 2b/3 clinical trial of selepressin for adults in septic shock: SEPSIS-ACT.Ann Am Thor Soc2018, 15(2):250-257.
  • Nakada T, Wacharasint P, Russell JA, Boyd J, Nakada E, Thai S, Shimada T,Walley KR. IL-20 genetic polymorphism is associatedwith altered clinical outcome in septic shock. J Inn Immun 2018 10(3):181 – 188. doi: 10.1159/000486104.
  • Fisher J, Linder A, Bentzer P, Boyd J, Kong HJ, Lee T, Walley KR, Russell JA. Is heparin- binding protein (HBP) inhibition a mechanism of albumin’s efficacy in human septic shock? Crit CareMed2018;46(5):e364-e374. doi: 10.1097/CCM.0000000000002996.
  • Annane D, Mira JP, Ware LB, Gordon AC, Christiani DC, Sevransky J, Buchman TG, Heagerty PJ, Wellman HF, Neira, M, Mancini ADJ, Walley KR, Russell JA. Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis. Ann Int Care2018, 8:16.
  • Russell JA. Vasopressin vs. norepinephrine in CVS surgery.Anesthesiology2018, 128(1):230-231.
  • Russell JA, Rush BR, Boyd JH. Pathophysiology of septic shock.Crit Care Clinics2018, 34:43–61.
  • Lee JGH, Genga KR, Pisitsak C, Boyd JH, Leung AKK, Russell JA, Walley KR. Survival benefit of a low ratio of visceral to subcutaneous adipose tissue depends on LDL clearance versus production in sepsis. Crit Care2018, 22:58. doi: 10.1186/s13054-018-1985-1.
  • Genga KR, Shimada T, Boyd JH, Walley KR, Russell JA. The understanding and management of organism toxicity in septic shock. J Innate Immunity May 15, 2018:1 – 13. (DOI:10.1159/000487818).
  • Russell JA, Lee T, Singer J, de Backer D, Annane D. Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials. J Crit Care2018, 47:333 – 337. May 12. doi: 10.1016/j.jcrc.2018.05.003.
  • Wiskar KJ, Celi LA, McDermid RC, Walley KR, Russell JA, Boyd JH, Rush B. Patterns of palliative care referral in patients admitted with heart failure requiring mechanical ventilation. Am J Hosp Pall Care2018, 35(4):620 – 626.
  • Russell JA, Spronk P, Walley KR. Using multi ‘omics strategies for novel therapies in sepsis. Int Care Med 2018, 44(4):509 – 511.
  • Annane D, Ouanes-Besbes L, de Backer D, Du B, Gordon AC, Hernandez G, Olsen K, Osborn T Peake S, Russell JA, Zanotti S. A global perspective on vasoactive agents in shock. Int Care Med2018,44(6):833-846. doi: 10.1007/s00134-018-5242-5.
  • Gordon AC, Russell JA. Innovation and safety in critical care: should we collaborate with the industry? Pro.Int Care Med 2018, 44(12):2276- 2278.doi: 10.1007/s00134-018-5306-6.
  • Russell JA, Wellman H, Walley KR. Vasopressin versus norepinephrine in septic shock: A propensity scored matched efficiency retrospective cohort study in the VASST coordinating center hospital. J Int Care 2018, 6:73.doi.org/10.1186/s40560-018-0344-2
  • Trinder M, Roveran Genga K, Kong HJ, Lo C, Li X, Cirstea M, Russell JA, Walley KR, Boyd JH, Brunham LR.Cholesteryl ester transfer protein genotype influences high-density lipoprotein levels and survival during sepsis. Am J Resp Crit Care Med 2018, 199(7):854-862. doi: 10.1164/rccm.201806-1157OC.
  • Bhatraju PK, Zelnick lr, Herting J, Katz R, Mikacenic C, Kosamo S, Morrell ED, Robinson-Cohen C, Calfee CS, Christie JD, Liu KD, Matthay MA, Hahn WO, Dmyterko V, SlivinskiNSJ Russell JA, Walley KR, Christiani DC, Liles C, Himmelfarb J, Wurfel MM. Identification of Acute Kidney Injury sub-phenotypes with differing molecular signatures and response to vasopressin therapy.Am J Resp Crit Care Med 2018, 199(7):863-872. doi: 10.1164/rccm.201807-1346OC.
  • Russell JA. When and how to use predictive biomarkers for corticosteroid treatment of shock.Crit Care 2018. 22:318. https://doi.org/10.1186/s13054-018-2254-z.
    VincentJL, NielsenND, ShapiroNI, GerbasiME, GrossmanA, Doroff R, ZengF, YoungP, Russell JA. Mean arterial pressure and mortality in patients with distributive shock:A retrospective study based on MIMIC-III. Ann Int Care 2018,8:107. doi: 10.1186/s13613-018-0448-9.
  • Roveran Genga K, Trinder M, Kong HJ, Leung AKK, Shimada T, WalleyKR, Russell JA, Brunham L, Francis GA, Boyd JH. CholesterylesterTransfer Protein (CETP) genotype R468Q is associatedwith increased risk of sepsis-associated Acute Kidney Injury (AKI). Sci Reports 2018, 8:16764. doi: 10.1038/s41598-018-35261-2.
  • Roveran GengaK, LoC, CirsteaMS, WalleyKR, RussellJA, LinderA, FrancisGA, BoydJH. The impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors.eBioMedicine2018,38:257-264.
  • Kong J, Boyd JH, Russell JA, Walley KR. Low LDL levels are associated with, but do not causally contribute to, increased mortality in sepsis. Crit Care Med 2019, 47(3):463 – 466.
  • Walley KR, Boyd JH, Kong J, Russell JA. PCSK9 loss-of-function genotype is beneficial in septic shock while HMGCR genotype is not: Lack of LDL effect. Crit Care Med2019 (In press).
  • Fisher J, Linder A, Caironi P, Russell JA. Hypoalbuminemia and the risk of acute kidney injury in sepsis.Crit Care Med2019 (In press).
  • Pickkers P, Russell JA. Treatment with a polymyxin B filter to capture endotoxin in sepsis patients. Is there a signal for therapeutic efficacy?Int Care Med 2019, 45(2):282-283.
  • NakadaT, Takahashi W, Nakada E, Shimada T, Russell JA, Walley KR.Genetic polymorphisms in sepsis and cardiovascular disease. Do similar risk genes suggest similar drug targets? Chest 2019 (Published online January 17, 2019). https://doi.org/10.1016/j.chest.2019.01.003
  • Russell JA, Gordon AC, Walley KR. Early may be better – early low-dose norepinephrine in septic shock. Am J Resp Crit CareMed2019;199(9):1049-1051. electronic access – https://www.atsjournals.org/doi/pdf/10.1164/rccm.201901-0083ED.
  • Linder A, Fjell C, Inghammer M, Hsu J, Walley KR, Boyd J, Russell JA. Specific pathogens but not bacterial gram type determine the inflammatory response in human septic shock. J Innate Immunity 2019 (In press).
  • Williams MD, Russell JA. Terlipressin or norepinephrine in septic shock: do we have the final answer?J Thor Dis2019 (Invited editorial in press).
  • NagendranM, RussellJA, WalleyKR, BrettSJ, PerkinsGD, HajjarL, MasonAJ, AshbyD, GordonAC. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials.Int Care Med2019 (In press).
  • Genga KR, Boyd J, Russell JA. Once or twice daily screening for weaning the critically ill – have we set our sights too low?Crit Care Med2019(Invited editorial in press).
Awards & Recognition:

Recent Awards

  • Recipient of the 2017 Aubrey J. Tingle Prize of the Michael Smith Foundation for Health research (MSFHR). Created in honour of MSFHR’s founding president & CEO, this award is given annually to a British Columbia clinician scientist whose work in health research has had a significant impact on advancing research and improving health, and the health system, in BC and beyond.
  • 2017, 2018: Ranked by Expertscape as: #1 in world in Septic shock, norepinephrine and vasopressin and #2 in world in sepsis and shock.